Clinical studies and real-life practice all indicate that the efficacy of real-time continuous glucose control (RT-CGM) closely depends on the selection of patients. Moreover, in these days of healthcare cost containment, the lack of clear identification of patients eligible for RT-CGM could limit its adoption and diffusion. Taking an evidence-based approach, with their daily practical experience, the authors have reviewed clinical studies, clinical guidelines and reimbursement indications in order to identify the categories of patients who are most likely to benefit from this recent technology. This consensus panel aims to identify criteria for patient selection in order to maximize the clinical benefit while, at the same time, ensuring the most appropriate use of healthcare resources.
|Translated title of the contribution||Consensus of an expert panel on the selection of patients eligible for real-time continuous glucose monitoring|
|Number of pages||9|
|Journal||Giornale Italiano di Diabetologia e Metabolismo|
|Publication status||Published - 2014|
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism